Dementia Discovery Fund (investor - Private Equity)

See something wrong or missing? Let us know
Offices:London

Dementia Discovery Fund is a £250 million specialist venture capital fund that invests in novel science to create meaningful new medicines. Dementia Discovery was launched in 2018 and is advised by SV Health Investors.

Average round investment:32.76M USD
Average number per year:1.6
Distribution: 2024 (1)2023 (1)2022 (1)2021 (3)2020 (2)
Mostly invests in: United Kingdom United Kingdom (8) Health services (8)
See the entire list

Showing 3 of 8 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Dementia Discovery Fund mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Dementia Discovery Fund

Name Criteria
Spain Iñaki Berenguer
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland Metellus AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States New Science Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Obvious Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United Kingdom Braavos Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Cleveland Avenue
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Canada CTI Life Sciences
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Belgium UCB Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Switzerland Pictet Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top